TIDMPRTC
PureTech Health PLC
17 May 2017
17 May 2017
PureTech Health plc
PureTech Health's Sync Project Announces New Investors and
Accelerates Development of Personalised Music Health Platform
PureTech Health plc ("PureTech", LSE: PRTC), an advanced,
clinical-stage biopharmaceutical company, is pleased to note that
Sync Project, a PureTech Health subsidiary, is welcoming new
investors as it accelerates development of its proprietary,
physiologically-responsive music health platform. To date, Sync
Project has raised $5 million in financing, which includes funds
from new investors Greylock Partners (via Discovery Fund), Reid
Hoffman, Esther Dyson, David Shaw, and Digital Garage. Sync Project
aims to validate interventions in both large-scale consumer
experiments and controlled clinical studies in conditions such as
stress, sleep, anxiety, and pain.
Mike MacLean, Chief Financial Officer of PureTech Health, said:
"We're pleased with the support that these prominent new investors
have provided to Sync Project as the team continues to advance
their precision medicine platform using music. PureTech Health has
been at the forefront of developing non-invasive digital
interventions across a range of conditions, and we look forward to
the future progress of Sync Project's technology."
The full text of the announcement from Sync Project is as
follows:
Sync Project Announces New Investors
and Accelerates Development of Personalised Music Health
Platform
Funds are being used to advance physiologically-responsive music
therapies
BOSTON, Massachusetts, May 17, 2017 - Sync Project, Inc., a
Boston-based company developing music as a personalised treatment
across a range of conditions, is accelerating development of its
physiologically-responsive music health platform. To date, Sync
Project has raised $5 million in financing from investors Reid
Hoffman, Greylock Partners (via Discovery Fund), Esther Dyson,
David Shaw, Digital Garage, and PureTech Health. The company aims
to validate interventions in both large-scale consumer experiments
and controlled clinical studies in conditions such as stress,
sleep, anxiety, and pain.
"Developing music as precision medicine requires the right mix
of people and funding that bridge consumer technology, music, and
biotech," said Marko Ahtisaari, CEO and Co-founder. "Our investors,
advisors, and team are just such a mix. With the support of our
investors, Sync Project is accelerating the development and
validation of generative music for health."
"We are excited about the Sync Project team and how they are
using artificial intelligence to create a new kind of personalised
music that responds to your physiology to improve health," said
Reid Hoffman, partner at Greylock Partners.
Sync Project is building a unique data set on the biometric
impact (e.g., heart rate, brain activity, and sleep patterns) of
certain structural properties of music (e.g., beat, key, and
timbre). Datasets generated through Sync Project's consumer
initiatives will be further validated through controlled clinical
trials in individuals suffering from sleep disorders, anxiety, and
pain, among others. Sync Project aims to commercialise the clinical
applications of this platform and deliver a personalised, low-cost,
non-invasive therapy, across a range of conditions.
Sync Project's generative music platform is based on scientific
research into the health effects of music. Recent research has
shown that music can modulate neural systems like the dopamine
response, autonomic nervous system, and other key pathways related
to stress, movement, learning, and memory. This body of research
shows that music affects some of the same neural pathways that are
regulated by pharmaceuticals such as psychostimulants and suggests
that music may hold significant therapeutic potential.
Earlier this year, Sync Project launched unwind.ai, the first
global experiment using algorithmically-generated music to
potentially improve relaxation prior to sleep. Anyone with a
smartphone can participate free of charge and contribute to a
global data set on how music affects stress. Designed in
collaboration with critically-acclaimed musicians, Sync Project's
generative music is personalised to an individual's unique
physiology.
About Sync Project
Sync Project is developing music as precision medicine. Sync
Project's generative music platform builds on scientific research
into the health effects of music with a unique data set and machine
learning that analyses musical attributes (like tempo and timbre)
and their impacts on biometrics (like heart rate, brain activity,
and sleep patterns.) Insights from Sync Project's consumer
initiatives will be further validated through controlled clinical
trials in individuals suffering from sleep disorders, anxiety, and
pain, among others. Sync Project aims to commercialise the clinical
applications of their platform and deliver a personalised,
low-cost, non-invasive therapy, across a range of conditions. Sync
Project was co-founded by Marko Ahtisaari, Yadid Ayzenberg, Ketki
Karanam, and PureTech Health (LSE: PRTC;
www.puretechhealth.com).
Sync Project's advisors and Board comprise a distinguished and
diverse team of science, music, health and technology experts
committed to uncovering the untapped potential of music's ability
to improve health: Robert Zatorre, Ph.D., Professor of Neurology
and Neurosurgery at the Montreal Neurological Institute at McGill
University; Adam Gazzaley, M.D., Ph.D., Director of the
Neuroscience Imaging Center and Professor of Physiology, Psychology
and Psychiatry at the University of California, San Francisco;
Tristan Jehan, Ph.D., Founding Chief Technology Officer of The Echo
Nest (Spotify); Peter Gabriel, six-time Grammy Award-winning
British singer-songwriter; Annie Clark (St. Vincent), award-winning
American singer-songwriter and multi-instrumentalist; Jon Hopkins,
classically trained British pianist, critically acclaimed recording
artist, Ivor Novello nominated composer of film scores, and
prominent producer/collaborator; Esa-Pekka Salonen, Principal
Conductor and Artistic Advisor of the Philharmonia Orchestra in
London and Conductor Laureate for the Los Angeles Philharmonic; and
Board Members Joi Ito, Director of the Massachusetts Institute of
Technology Media Lab, Marjorie Scardino, DBE, FRSA, Chairman of the
MacArthur Foundation, Board member of Twitter and former CEO of
Pearson, Steven Holtzman, CEO of Decibel Therapeutics, and Daphne
Zohar, Co-Founder and the Chief Executive Officer of PureTech
Health. For more information visit syncproject.co or connect with
us on Twitter @syncprojectco.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is an advanced,
clinical-stage biopharmaceutical company developing novel medicines
that modulate the adaptive human systems. PureTech's therapies
target the dysfunctions in the immune, nervous, and
gastro-intestinal systems by addressing the underlying
pathophysiology of disease from a systems perspective rather than
through a single receptor or pathway. The Company is advancing a
rich pipeline that includes multiple human proof-of-concept studies
and pivotal or registration studies expected to read out over the
next 12-18 months. PureTech Health's growing research and
development pipeline has been developed in collaboration with some
of the world's leading scientific experts, who along with
PureTech's experienced team and a stellar Board identify, analyse
and advance very selectively the opportunities the Company believes
hold the most promise for patients. This experienced and engaged
team places PureTech Health at the forefront of ground-breaking
science and technological innovation and leads the Company between
and beyond existing disciplines. For more information, visit
www.puretechhealth.com or connect with us on Twitter
@puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
PureTech Health FTI Consulting
Allison Mead Ben Atwell, Matthew
+1 617 651 3156 Cole, Rob Winder
amead@puretechhealth.com +44 (0) 20 3727
1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADBGDULDBBGRL
(END) Dow Jones Newswires
May 17, 2017 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024